anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients undergo collection of tissue and blood samples prior to initiation of treatment, during treatment, post treatment and at disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected, if available. Patient medical records are reviewed, and data is collected for at least 5 years.
NanoFUSE® is indicated to be placed into bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure (i.e. the posterolateral spine and pelvis.) These defects may be surgically created osseous defects created from traumatic injury to the bone. NanoFUSE® must be used with autograft as a bone graft extender in the posterolateral spine. This product provides a bone graft substitute that remodels into the recipient's skeletal system. Radiographic success will be the primary judgement of success. All patient's achieving fused or probably fused status will be judged as a success.
INTRODUCTION: Iatrogenic injury during urethral catheterization is a common reason for inpatient urologic consultation and is associated with increased morbidity and resource utilization. Literature defining the patient population, interventions, or outcomes associated with traumatic catheterization is scarce.
METHODS: We performed a retrospective review of consults for adult urethral catheterization at a single tertiary care center (July 2017-December 2019), with focus on patient characteristics and complications. Traumatic urethral catheterization was defined as catheterization by the primary team with at least 1 of these conditions: gross hematuria, meatal blood, or cystoscopic evidence of urethral trauma. Characteristics collected included urologic history, catheterization circumstances, procedural intervention, and subsequent visits.
RESULTS: Three hundred urology consults for urethral catheterization were identified, including 98 (33%) traumatic events (5.3 incidents/1000 catheters placed). All traumatic catheterization consults were in men (median age 69 years). Most (71%) patients sustaining injury had significant urologic history (eg, benign prostatic hyperplasia, urethral stricture). Sixty-three (64%) consults were determined to be uncomplicated (not requiring any procedural intervention for catheter placement). Gross hematuria was the most common sequela (50% of patients). The 30-day catheter-associated urinary tract infection rate was 13%, and 2 patients developed sepsis. Complications required a total of 52 additional hospital admission days, 19 of which were intensive-care level, as well 113 outpatient urology visits.
CONCLUSIONS: Traumatic urethral catheterization is associated with increased need for procedural intervention, risk of catheter-associated urinary tract infection, and additional resource utilization. Further studies on traumatic catheterization are needed to guide systemic efforts for minimizing injury and cost.
The trial is a multi-centre, open-label randomised phase II study in patients with androgen-independent prostate cancer (AIPC), with a lead-in combination tolerance study. The aim of the lead-in phase is to establish the maximum tolerated dose (MTD) of PI-88 administered either 4 days/week or 7 days/week) in combination with fixed doses of docetaxel (75 mg/m\^2 every 21 days) and prednisone (5 mg twice daily). In the randomized phase II component, patients will receive PI-88 at the MTD, either 4 days/week or 7 days/week, in combination with docetaxel and prednisone. The patients will receive up to 10 treatment cycles of the combination therapy. Response to treatment will be assessed by measuring serum levels of prostate specific antigen (PSA). Other efficacy measures will include radiological assessment, progression-free survival, overall survival and quality of life.
OBJECTIVE: The objective is to describe the clinical features, treatments, and outcomes of a case series of patients with Onodi cell mucocele, with or without cholesterol granuloma (CG).
MATERIAL AND METHODS: We retrospectively reviewed the medical records of eight patients diagnosed with Onodi cell mucocele at a single tertiary care university hospital in Beijing, China, between January 2017 and September 2020. Data regarding nasal symptoms, ocular symptoms, sinus computed tomography findings, treatments, histopathological results, and clinical outcomes were extracted.
RESULTS: We identified eight patients (six men and two women) of an average age of 48.1 (range, 26-70) years. Four patients presented nasal symptoms. Three patients presented ocular symptoms. Among them, one patient experienced concurrent nasal and ocular symptoms. Two patients were diagnosed based on a physical examination in the absence of nasal or ocular symptoms. All patients underwent endoscopic sinus surgery. The pathological specimens showed mucocele in four cases and mucocele with CG in the other four cases. Among the four cases with CG, three cases presented with decreased vision. After endoscopic sinus surgery, one patient recovered completely, and two patients showed significant improvement.
CONCLUSION: If Onodi cell opacity is observed, especially with optic neuropathy, mucocele and CG are important differential diagnoses. The combination of mucocele and CG is more likely to promote bone destruction and cause serious optic neuropathy than simple mucocele. Endoscopic sinus surgery is appropriate. Diagnoses, treatments, and follow-up should be performed by a multidisciplinary team.
PCT No. PCT/IB96/00400 Sec. 371 Date Oct. 29, 1997 Sec. 102(e) Date Oct. 29, 1997 PCT Filed Mar. 23, 1995 PCT Pub. No. WO96/29082 PCT Pub. Date Sep. 26, 1996The present invention provides a process of prolonging organ allograft survival in an organism comprising down-regulating Th1 activity in the organism. The down-regulation of Th1 activity is accomplished either by infecting the organism with an effective Th2 up-regulating amount of a nematode or by administering to the organism an effective Th2 up-regulating amount of a soluble extract of a nematode. Exemplary and preferred nematodes for use in a process of the present invention are of the genus Nipostrongylus , Trichuris, Ascaris or Caenorhabditis. Most preferred is the nematode Nipostrongylus brasiliensis. A process of the present invention is particularly useful in prolonging kidney allograft survival.
Tranexamic Acid (Cyklokapron) Loading Dose 10mg/kg given over 15 minutes, followed by 1mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
Survivors of pediatric bone sarcoma are at-risk for developing chronic pain. Cognitive behavioral therapy (CBT) is an effective non-pharmacologic treatment for chronic pain, and can be delivered remotely to reduce access barriers. However, these programs have not been adapted to be culturally sensitive to underserved populations thus limiting their reach, usefulness, and uptake. The investigators propose to culturally tailor an established, evidence-based mobile CBT program for chronic pain to Black and Hispanic adolescent survivors of childhood cancer. Once the program is fully adapted, we propose to pair the culturally adapted mobile CBT program with remotely delivered transcranial direct current stimulation (tDCS), which may enhance pain control in survivors. The investigators will conduct a 6-week feasibility study in a racially/ethnically diverse sample of non-Hispanic White, non-Hispanic Black, and Hispanic adolescent survivors of pediatric bone sarcoma with chronic pain using culturally adapted CBT paired with remote tDCS. Study results will inform the development of a randomized clinical trial.
PROBLEM TO BE SOLVED: To obtain a matrix agent that can efficiently produce in shortened time sustained release capsules that can stably release the active ingredients continuously for a long time by using polyglycerol fatty acid ester and oil that is fluid at normal temperature. SOLUTION: One pt.wt. of polyglycerol fatty acid ester is mixed with 0.1-10 pts.wt. of oil that is fluid at ordinary temperature as a middle-size chain fatty acid triglyceride to prepare the sustained release matrix agent for oral preparation that is semisolid at normal temperature. To this matrix agent, are added active ingredients for dispersion or dissolution. Then, the resultant dispersion or solution is capsuled to prepare the objective sustained release capsule preparation. This matrix agent can gradually release the main active ingredients into digestive tracts and the capsule preparation usign the same can be miniaturized and enables uniform filling. In addition, drug slightly soluble in water and slightly absorbable can be dissolved in an excipient thereby increasing its bioavailability.
Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.

The most important metabolic pathway for levonorgestrel occurs in the reduction of the Δ4- and the 3-oxo-group as well as hydroxylations at positions 2α , 1β, and 16β, followed by conjugation. Most of the metabolites that circulate in the blood are sulfates of 3α , 5β -tetrahydro-levonorgestrel, while excretion occurs predominantly in the form of glucuronides. Some of the parent levonorgestrel also circulates as the 17β-sulfate. In-vitro studies on the biotransformation of levonorgestrel in human skin did not indicate any significant metabolism of levonorgestrel during skin penetration.
This study aims to delineate the causal relationships between idiopathic tinnitus in different stages and severity and the morphological properties in specific brain regions. We utilized a two-sample bidirectional Mendelian randomization (MR) analysis to ascertain the causal effects of brain structural attributes on varying severities and stages of tinnitus. Our approach involved harnessing genetic variables derived from extensive genome-wide association studies as instrumental variables, centered mainly on pertinent single-nucleotide polymorphisms associated with tinnitus. Subsequently, we integrated this data with brain structural imaging inputs to facilitate the MR analysis. We also applied reverse MR analysis to pinpoint the critical brain regions implicated in the onset of tinnitus. Our analysis revealed a demonstrable causal relationship between tinnitus and brain structural alterations, including changes primarily within the auditory cortex and hub regions of the limbic system, as well as portions of the frontal-temporal-occipital circuit. We found that individuals exhibiting cortical thickness alterations in the bilateral peri-calcarine and right superior occipital gyrus might have previously experienced tinnitus. Changes in the cortical areas of the right rectus, left inferior frontal gyrus, and right pars-orbitalis appeared unrelated to tinnitus. Furthermore, moderate tinnitus patients showed more pronounced structural alterations. This study substantiates that tinnitus could instigate substantial structural alterations mainly within the auditory-limbic-frontal-visual system, while the reciprocal causality was not supported. Moreover, the data underscores that moderate, rather than severe, tinnitus precipitates the most significant structural changes. Morphological alterations in several specific brain areas either indicate a history of tinnitus or bear no relation to it.
PROBLEM TO BE SOLVED: To obtain the subject composition usable by massage through taking it on one's hand without any tool and useful as a cleansing agent composition especially for the body by designing the composition to have a specific viscosity and specific pseudoplasticity. SOLUTION: This composition is such as to have a viscosity with the number of revolutions of 0.5 s-1 at 30 deg.C as 800-20,000 mPa.s, and the ratio of viscosity η1 with the number of revolutions of 0.1 s-1 to viscosity η2 with the number of revolutions of 1 s-1 (η1 to η2) as >=3. The above viscosity and pseudoplasticity can be realized, for instance, by formulating a surfactant-containing liquid such as of a polyoxyethylene alkyl ether sulfate salt with a thickening agent capable of imparting pseudoplasticity (e.g. an alkyl acrylate/methacrylate copolymer). It is preferable to include e.g. powder, particles, beads in this composition.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to bicyclic compounds with nucleus formed by two condensed six-membered cycles, for example, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene or tetralone substituted with both acid and basic functional groups and these compounds can be used for inhibition of erythrocytes aggregation. Invention relates to a bicyclic compound of the formula (I)   where: B 1 ,B 2 ,B 3 ,B 4  are taken independently among carbon and nitrogen atoms at condition that at least two of B 1 ,B 2 ,B 3 ,B 4  are carbon atoms; R 3  - an acid group; n = 2-6; R 0  is taken among hydrogen, halogen atom and can be similar or distinct or =O at condition that if R 0  is= 0, n= O then only one of B 1 ,B 2 ,B 3  and B 4  can be nitrogen atom; the binding group - (L) is a bond or divalent substituted or unsubstituted chain containing from 1 to 10 atoms taken among the group including carbon, nitrogen and oxygen atoms; Q - an organic group containing the basic radical. Invention describes a pharmaceutical composition based on compounds of the formula (I) that inhibits platelets erythrocytes aggregation. EFFECT: valuable property of compounds. 11 cl, 26 dwg, 1 tbl, 44 ex
The dose is dependent upon the age, weight and clinical condition of the patient. 

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. 

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See PRECAUTIONS.)
The invention belongs to the technical field of biological products and cosmetics, and discloses a transdermal heptapeptide, a cosmetic composition containing the transdermal heptapeptide and a preparation method of the transdermal heptapeptide. The amino acid sequence of the transdermal heptapeptide is shown in SEQ ID NO. 1. The cosmetic composition comprises transdermal heptapeptide, hyaluronic acid and water, wherein the concentration of the transdermal heptapeptide is 20-50 mu g/mL, and the concentration of the hyaluronic acid is 50-80 mg/mL. The preparation method comprises the steps of connecting the transdermal heptapeptides in series, transferring the transdermal heptapeptides into escherichia coli for amplification culture, and performing enzyme digestion to remove the connection in series to obtain the transdermal heptapeptides. The beauty composition has the advantages that the transdermal peptide can effectively permeate into the skin, the skin elasticity is increased, the skin problems such as fine lines and the like are solved, and the effect of the transdermal peptide is fully improved while the moisturizing capability of the beauty composition is effectively improved by combining the transdermal peptide and hyaluronic acid in a specific ratio; the preparation method can be used for producing transdermal heptapeptide in an expanded way by biotechnology such as recombinant engineering bacteria, has high purity, and is suitable for large-scale production.
Patients will first undergo visit V1 (screening and enrolment). On day 0 they will have the surgery for VA creation (V2) and then the study follow-up visits will take place i.e., between 0 and 14 days, at 3 months, 6 months, 1 year and 2 years after VA surgery (V3-V7).
Emergency general surgery (EGS) represents illnesses of diverse pathology with urgent/emergent treatment needs being the common denominator.A characteristic feature of EGS is its limitation in patient preparation. It is difficult and often impossible to eliminate certain patient dependent factors to reduce the operative risk. It has been reported that the annual case rate in the EGS population is (1,290 per 100,000) higher than the sum of all cancer diagnoses. The EGS burden is substantial and continues to increase. The elderly patient population represents 48% of the overall EGS population. With the increase in the prevalence of atherosclerotic disease in the elderly there has been an increase in the use of antiplatelets and anticoagulants.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to pharmaceutical industry and medicine. Method of purification consists in the following: extract of green tea is washed with methylene chloride, or chloroform, or trichloroethylene by slurryfication with further mixing of suspension at room temperature during 20-40 minutes, and ratio of green tea extract and chlorine-containing hydrocarbon constitutes 1:28-30. Then sediment is separated and dried at temperature 28-32C and residual pressure 12-14 mm Hg during one and a half hours. Medicine represents gel, containing purified by claimed method extract of green tea with 70-75% content of epigallocatechine-3-gallate (EGCG) and additional components with specified ratio in wt %. Gel is applied on damaged areas of face and body skin in thin layer until cvomplete drying 1-3 times per day during 5 days - 12 weeks. ^ EFFECT: gel has expressed antihyperplastic, anti-inflammatory and antioxidant properties, activates natural process of tissue regeneration, normalises metabolic processes, inhibits premature ageing, increases skin stability against unfavorable iimpact of environment. ^ 3 cl, 2 tbl, 10 ex
PCT No. PCT/JP97/00073 Sec. 371 Date Jul. 21, 1998 Sec. 102(e) Date Jul. 21, 1998 PCT Filed Jan. 17, 1997 PCT Pub. No. WO97/27190 PCT Pub. Date Jul. 31, 1997This invention relates to novel thiazolylbenzofuran derivatives of formula (I) wherein R1 is lower alkyl, L is single bond or lower alkylene optionally substituted with aryl, oxo or hydroxy, and Q is a heterocyclic group optionally substituted with one or more suitable substituent(s); or lower alkoxy substituted with aryl which is substituted with one or more suitable substituent(s) and at least one of which is lower alkoxy optionally substituted with cyano, protected carboxy, carboxy, lower alkylene, a heterocyclic group optionally substituted with oxo, or amidino optionally substituted with hydroxy or lower alkoxy, or its salt, which possess activities as leukotriene and SRS-A antagonists or inhibitors.
The invention provides compound essential oil for treating skin diseases, which consists of the following components: sweet wormwood essential oil, frankincense essential oil, white tea essential oil and magnolia leaf essential oil, wherein the volume ratio is 4. The compound essential oil disclosed by the invention is used for treating skin diseases by repairing skin barriers, resisting inflammation and resisting allergy. The sweet wormwood essential oil, frankincense essential oil and magnolia leaf essential oil are prepared from sweet wormwood (Artemisia annua L.) (of Compositae) Artemisia    annua L . ) Essential oils obtained by steam distillation of raw materials Boswellia carterii (Boswellia carterii) and magnolia leaves (Michelia alba); the white tea essential oil is prepared from the plant Mao Baicha (Theaceae) Camellia sinensis(L .)O .Ktze ) Is prepared from volatile oil obtained by supercritical carbon dioxide extraction and molecular distillation. The four kinds of essential oil are evenly mixed according to a certain volume ratio, and the compound essential oil of the invention is obtained.
Postthoracotomy pain syndrome (PPS) is defined as a persistent and/or recurrent pain or burning sensation along the thoracotomy scar at 3 months after surgery. The pain is very significant, given that 3 to 5% of postthoractomy patients report it as being severe, and approximately 50% of patients report limitations in their activities of daily living. Little is known about the origin of this pain, but it seems that the intensity of acute postoperative pain is the best predictor of it. Lidocaine infusion could be a possible approach to reducing the prevalence of PPS. Recently, a meta-analysis concluded a modest but statistically significant reduction of pain severity in the first four postoperative hours measured by the visual analogue scale (mean difference, -0.84; 95% CI, -1.10 to -0.59). However, a more recent meta-analysis found that only limited clinical data and biological plausibility support lidocaine infusions for the prevention of postoperative persistent pain (odds ratio, 0.29; 95% CI, 0.18 to 0.48). This study was designed to investigate whether lidocaine infusion after video-assisted thoracoscopic surgery (VATS) would lower PPS at postoperative 3 and 6 month.
FIELD: medicine. SUBSTANCE: method involves applying reflex correction therapy course by means of mechanical compression and petrissage applied to radical and paravertebral zones in dorsum tissues at the place of abdominal and thoracic cavity sympathetic stem projection. Then a series of strikes is made with hand palm base thenar-hypothenar area in the direction from vertebral column center to periphery. The reflex correction therapy course is combined with respiratory and physical training Yoga exercise course aimed at improvement of the vegetative nerve structure blood supply of the spinal cord and tendinomscular structures of the vertebral column. A tincture is administered at a dose of 50 drops 3 times a day during 1 month. The drops have Crataegus L. 1 part, Leonurus L. 2 parts, Corvalol 4 parts. EFFECT: enhanced effectiveness of treatment; excluded recurrence of the disease.
The invention provides composition for treating chicken infectious gonads gastritis. The composition comprises, by weight, 35-45 parts of coptis chinensis, 55-65 parts of astragalus membranaceus, 15-25 parts of aspergillus niger, and 25-35 parts of lactic acid bacteria. The preparation having Chinese herbal medicine combined with microbial flora has great treatment effect on chicken infectious gonads gastritis. With coordinative action among Chinese herbal medicine, aspergillus niger and lactic acid bacteria, immunity of human body is strengthened during treatment of chicken infectious gonads gastritis, and cure rate and efficacy are increased accordingly. Meanwhile, the composition has no tolerance and drug resistance to chickens and low drug residues. The composition is made of materials easily obtainable, and is convenient to prepare, highly stable in storage, and suitable for industrialized production.